FIELD: medicine.
SUBSTANCE: in order to increase apoptosis in mammalian cells, combination, containing efficient amount of polypeptide Apo2L/TRAIL and EGFR inhibitor, representing N-(3-ethinylphenyl)-6,7-bis(2-methoxyetoxy)-4-chinasolinamine is used.
EFFECT: invention makes it possible to use combination efficiently to increase apoptosis, in which sinergetic activity of claimed composition is demonstrated.
15 cl, 12 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| APOPTOTIC Apo2L/TRAIL SENSITIVITY BY TESTING GalNac-T14 EXPRESSION IN CELLS/TISSUES | 2006 |
|
RU2416097C2 |
| ANALYSES AND METHODS USING BIOMARKERS | 2005 |
|
RU2410438C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| APOPTOSIS DETECTION TECHNIQUES AND REAGENTS | 2007 |
|
RU2450273C2 |
| ANALYSES AND METHODS OF BIOMARKER APPLICATION | 2006 |
|
RU2409817C2 |
| ANALYSES AND METHODS WITH APPLICATION OF BIOMARKERS | 2005 |
|
RU2431676C2 |
| METHOD OF PURIFYING APO-2 LIGAND/TRAIL VIA COLD CRYSTALLISATION | 2006 |
|
RU2435781C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
